Diligent Announces Shiza Shahid, Moisés Naím, Michael Montelongo, Veena Ramani and More to Deliver Impactful Sessions at the Fourth Annual Modern Governance Summit
14.9.2022 21:37:00 EEST | Business Wire | Press release
Diligent, the global leader in modern governance providing SaaS solutions across governance, risk, compliance, audit and ESG, today announced keynote speakers and agenda highlights for its annual Modern Governance Summit (MGS), taking place in Austin, Texas and online between September 12-14, 2022.
World-renowned leaders will take the stage to explore key issues like risk and strategy; ethics and compliance; environmental, social and corporate governance (ESG); digital transformation and more. Attendees will have the opportunity to network with peers and hear from industry experts in impactful sessions like “The World Hangs in the Balance: Getting ESG Right”; “Living Your Purpose: Putting Your Values and Ethics First in Business”; “The Evolving Risk Landscape – Implications of Geopolitical and Financial Risk”; “What Has Changed (and what hasn't) Since SOX”; and “The Courage to Lead: What it Takes to Build a Purpose-Driven Enterprise.” A full agenda can be found here.
Just a few of the inspirational speakers at this year’s MGS include:
- Shiza Shahid, an entrepreneur, investor, technologist, and impact leader, co-founded the Malala Fund with Nobel Prize winner Malala Yousafzai and led the organization as founding CEO. She is now the co-founder of Our Place, a mission-driven e-commerce startup that is creating products and telling stories that celebrate cultural traditions and reinvest in communities, through the lens of food and home-cooking. Shiza will deliver a session on putting values and ethics first in business.
- Moisés Naím, internationally syndicated columnist and best-selling author. In the early 1990s, Dr. Naím served as Venezuela’s Minister of Trade and Industry, as director of Venezuela’s Central Bank, and as executive director of the World Bank. Dr. Naím will be a keynote speaker discussing geopolitical risk and strategy.
- Sherron Watkins, former Vice President of Corporate Development at the Enron Corporation, whose exposure of corporate misconduct paved the way for the enactment of SOX corporate reform law. Sherron will be part of a panel discussion on what has changed – and what hasn’t – since Sarbanes-Oxley Act was enacted 20 years ago.
- Cynthia Cooper, accountant who formerly served as the Vice President of Internal Audit at WorldCom where her team exposed the largest accounting fraud in U.S. history. Cynthia will also be part of the panel on what has changed since SOX.
- The Honorable Michael Montelongo, President and CEO of GRC Advisory Services, LLC, and former Bush White House appointee who served as the 19th assistant secretary for financial management and CFO of the US Air Force and the first Latino in that role. Michael will join Cynthia Cooper and Sherron Watkins in the SOX panel discussion.
- Veena Ramani, Research Director at FCLTGlobal and expert in corporate governance, climate change and ESG issues. Veena will be part of panel discussions on preparing for shareholder and stakeholder ESG activism and getting ESG right.
- Enrique Acevedo, CBS Correspondent who has interviewed some of the world’s biggest leaders, including President Barack Obama, Melinda Gates, Kofi Annan and more. Enrique will moderate “The World Hangs in the Balance: Getting ESG Right.”
“Organizations today are navigating complex and ever-evolving business landscapes, where uncertainty is omnipresent,” said Brian Stafford, CEO of Diligent. “In this era, the role of governance, risk, compliance, audit and ESG professionals has become even more critical. We’re honored to be engaging with this community of leaders in person once again as we explore the intersection of performance, risk and purpose, and to welcome this year’s roster of world-renowned speakers.”
Now in its fourth year, the Modern Governance Summit is the largest governance, risk and compliance (GRC) event of the year bringing together thousands of leaders from board members to corporate secretaries, general counsels, chief compliance officers and other governance professionals. Designed to elevate GRC practices and explore key issues facing organizations today, attendees benefit from 2.5 days of thought leadership, networking and product training opportunities.
The event is open to the press and most sessions will be on the record. For more information and to register contact: press@diligent.com
About Diligent
Diligent is the global leader in modern governance, providing SaaS solutions across governance, risk, compliance, audit and ESG. Serving more than 1 million users from over 25,000 customers around the world, we empower transformational leaders with software, insights and confidence to drive greater impact and lead with purpose. Learn more at diligent.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220809005247/en/
Contact information
Media Contact
Julia Hanbury
Senior Communications Manager, Diligent
+1-604-669-4225
Jhanbury@diligent.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
